Literature DB >> 30830040

Antibody-suppressor CD8+ T Cells Require CXCR5.

Jason M Zimmerer1, Bryce A Ringwald2, Steven M Elzein2, Christina L Avila1, Robert T Warren1, Mahmoud Abdel-Rasoul3, Ginny L Bumgardner1.   

Abstract

BACKGROUND: We previously reported the novel activity of alloprimed CD8 T cells that suppress posttransplant alloantibody production. The purpose of the study is to investigate the expression and role of CXCR5 on antibody-suppressor CD8 T-cell function.
METHODS: C57BL/6 mice were transplanted with FVB/N hepatocytes. Alloprimed CD8 T cells were retrieved on day 7 from hepatocyte transplant recipients. Unsorted or flow-sorted (CXCR5CXCR3 and CXCR3CXCR5) alloprimed CD8 T-cell subsets were analyzed for in vitro cytotoxicity and capacity to inhibit in vivo alloantibody production following adoptive transfer into C57BL/6 or high alloantibody-producing CD8 knock out (KO) hepatocyte transplant recipients. Alloantibody titer was assessed in CD8 KO mice reconstituted with naive CD8 T cells retrieved from C57BL/6, CXCR5 KO, or CXCR3 KO mice. Antibody suppression by ovalbumin (OVA)-primed monoclonal OVA-specific t-cell receptor transgenic CD8+ T cells (OT-I) CXCR5 or CXCR3 CD8 T-cell subsets was also investigated.
RESULTS: Alloprimed CXCR5CXCR3CD8 T cells mediated in vitro cytotoxicity of alloprimed "self" B cells, while CXCR3CXCR5CD8 T cells did not. Only flow-sorted alloprimed CXCR5CXCR3CD8 T cells (not flow-sorted alloprimed CXCR3CXCR5CD8 T cells) suppressed alloantibody production and enhanced graft survival when transferred into transplant recipients. Unlike CD8 T cells from wild-type or CXCR3 KO mice, CD8 T cells from CXCR5 KO mice do not develop alloantibody-suppressor function. Similarly, only flow-sorted CXCR5CXCR3 (and not CXCR3CXCR5) OVA-primed OT-I CD8 T cells mediated in vivo suppression of anti-OVA antibody production.
CONCLUSIONS: These data support the conclusion that expression of CXCR5 by antigen-primed CD8 T cells is critical for the function of antibody-suppressor CD8 T cells.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30830040      PMCID: PMC6713619          DOI: 10.1097/TP.0000000000002683

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  80 in total

1.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand.

Authors:  T Kawai; D Andrews; R B Colvin; D H Sachs; A B Cosimi
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  CD8 T-lymphocyte-mediated regulation of ovalbumin-specific murine IgE responses.

Authors:  M J Thomas; P A MacAry; D M Kemeny
Journal:  Int Arch Allergy Immunol       Date:  1999 Feb-Apr       Impact factor: 2.749

3.  Rejection responses to allogeneic hepatocytes by reconstituted SCID mice, CD4, KO, and CD8 KO mice.

Authors:  G L Bumgardner; D Gao; J Li; J H Baskin; M Heininger; C G Orosz
Journal:  Transplantation       Date:  2000-12-27       Impact factor: 4.939

4.  T cytotoxic 1 and T cytotoxic 2 CD8 T cells both inhibit IgE responses.

Authors:  M J Thomas; P A MacAry; A Noble; P W Askenase; D M Kemeny
Journal:  Int Arch Allergy Immunol       Date:  2001 Jan-Mar       Impact factor: 2.749

5.  Critical role for IL-4 in the development of transplant arteriosclerosis in the absence of CD40-CD154 costimulation.

Authors:  S M Ensminger; B M Spriewald; H V Sorensen; O Witzke; E G Flashman; A Bushell; P J Morris; M L Rose; A Rahemtulla; K J Wood
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

6.  Intragraft interleukin-4 mRNA expression after short-term CD154 blockade may trigger delayed development of transplant arteriosclerosis in the absence of CD8+ T cells.

Authors:  S M Ensminger; B M Spriewald; O Witzke; K Morrison; A van Maurik; P J Morris; M L Rose; K J Wood
Journal:  Transplantation       Date:  2000-09-27       Impact factor: 4.939

7.  CD8(+) T cell knockout mice are less susceptible to Cowdria ruminantium infection than athymic, CD4(+) T cell knockout, and normal C57BL/6 mice.

Authors:  B Byrom; A F Barbet; M Obwolo; S M Mahan
Journal:  Vet Parasitol       Date:  2000-11-10       Impact factor: 2.738

8.  Requirement of the chemokine receptor CXCR3 for acute allograft rejection.

Authors:  W W Hancock; B Lu; W Gao; V Csizmadia; K Faia; J A King; S T Smiley; M Ling; N P Gerard; C Gerard
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

9.  CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function.

Authors:  P Schaerli; K Willimann; A B Lang; M Lipp; P Loetscher; B Moser
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

10.  Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production.

Authors:  D Breitfeld; L Ohl; E Kremmer; J Ellwart; F Sallusto; M Lipp; R Förster
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

View more
  9 in total

Review 1.  Follicular T-cell regulation of alloantibody formation.

Authors:  Mostafa T Mohammed; Peter T Sage
Journal:  Curr Opin Organ Transplant       Date:  2020-02       Impact factor: 2.640

2.  Antibody-suppressor CXCR5+ CD8+ T cellular therapy ameliorates antibody-mediated rejection following kidney transplant in CCR5 KO mice.

Authors:  Jason M Zimmerer; Jing L Han; Chelsea M Peterson; Qiang Zeng; Bryce A Ringwald; Clarissa Cassol; Sachi Chaudhari; Madison Hart; Jessica Hemminger; Anjali Satoskar; Mahmoud Abdel-Rasoul; Jiao-Jing Wang; Robert T Warren; Zheng J Zhang; Christopher K Breuer; Ginny L Bumgardner
Journal:  Am J Transplant       Date:  2022-02-15       Impact factor: 9.369

3.  Inverse Association Between the Quantity of Human Peripheral Blood CXCR5+IFN-γ+CD8+ T Cells With De Novo DSA Production in the First Year After Kidney Transplant.

Authors:  Jason M Zimmerer; Matthew W Basinger; Bryce A Ringwald; Mahmoud Abdel-Rasoul; Ronald P Pelletier; Amer Rajab; Ashraf El-Hinnawi; Hemant Parekh; Kenneth Washburn; Ginny L Bumgardner
Journal:  Transplantation       Date:  2020-11       Impact factor: 5.385

Review 4.  CXCR5+CD8+ T cells: A Review of their Antibody Regulatory Functions and Clinical Correlations.

Authors:  Steven M Elzein; Jason M Zimmerer; Jing L Han; Bryce A Ringwald; Ginny L Bumgardner
Journal:  J Immunol       Date:  2021-06-15       Impact factor: 5.426

Review 5.  Future prospects for CD8+ regulatory T cells in immune tolerance.

Authors:  Léa Flippe; Séverine Bézie; Ignacio Anegon; Carole Guillonneau
Journal:  Immunol Rev       Date:  2019-10-08       Impact factor: 12.988

Review 6.  CD8+ T Lymphocytes: Crucial Players in Sjögren's Syndrome.

Authors:  Huimin Zhou; Jun Yang; Jie Tian; Shengjun Wang
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

Review 7.  The Complex Role of Regulatory T Cells in Immunity and Aging.

Authors:  Lourdes Rocamora-Reverte; Franz Leonard Melzer; Reinhard Würzner; Birgit Weinberger
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 8.786

Review 8.  Harnessing CD8+CD28- Regulatory T Cells as a Tool to Treat Autoimmune Disease.

Authors:  Sabrina Ceeraz; Charlotte R Thompson; Richard Beatson; Ernest H Choy
Journal:  Cells       Date:  2021-11-01       Impact factor: 6.600

9.  The diagnostic role of PD-1+ CXCR5+ follicular helper CD8+ T cell in renal allograft dysfunction.

Authors:  Ji-Wen Fan; Lin Yan; Xue-Qiao Wang; Ya-Mei Li; Yang-Juan Bai; Xiao-Qi Ou; Zheng-Li Wan; Yi Li
Journal:  J Clin Lab Anal       Date:  2021-12-26       Impact factor: 2.352

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.